The Head & Neck Oncology Program of the Stanford Cancer Center seeks patients for three new clinical trials:
• Lapatinib plus radiation is for potentially curable previously untreated patients with advanced non-metastatic head and neck squamous cell cancer (HNSCC) who are not candidates for standard cisplatin-based chemoradiation.
• BIBW2992 is an orally available inhibitor of EGFR. This trial is for patients with recurrent or metastatic HNSCC.
• XL880 is an orally available inhibitor of both MET and VEGF that has been shown to have anti-cancer activity in several tumor types.
Details and contact information for these trials is available at http://cancer.stanford.edu/trials/adult/
Head_and_Neck_Cancer.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment